Abstract
Background: Aberrant protein translation is a key driver in cancer downstream of pro-oncogenic stimuli. The aberrant protein translation is frequently carried out by ribosomes that have cancer specific alterations providing an opportunity to selectively target “oncoribosomes.” Our unique synthetic chemistry generates novel macrolides that are Ribosome Modulating Agents (RMAs) capable of selectively targeting oncoribosomes. Wnt-pathway activated colorectal cancers (CRC) tend to be highly dependent on elevated protein translation capacity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
